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Reports of acute ischemic events after withdrawal of
calcium antagonist therapy in outpatients and during
bypass surgery in patients with prior angina at rest
prompted the examination of the effect of nifedipine
withdrawal in 81 patients who had completed a pro-
spective, double-blind randomized trial of nifedipine
versus placebo for rest angina. Thirty-nine patients
underwent bypass surgery for uncontrolled angina or
left main coronary artery disease. No significant differ-
ence between patients withdrawn from nifedipineor pla-
cebo was seen in the incidence of perioperative myo-
cardial infarction, hypotension requiring intraaortic
balloon counterpulsation, vasopressor or vasodilator re-
quirements or incidence of significant arrhythmias.
An additional 42 patients had completed 2 years on
a protocol consisting of nitrates and propranolol in ad-
dition to nifedipine or placebo. During a mean of 66
hours of continuous monitoring after withdrawal of ni-
Abruptly stopping treatment with vasoactive drugs may be
hazardous. Early reports (1-4) of myocardial infarction and
sudden death among munitions workers without coronary
artery disease suggested that rebound vasospasm occurs after
acute withdrawal from long-term nitrate exposure. Rapid
withdrawal of sodium nitroprusside is associated with hemo-
dynamic deterioration in patients with congestive heart fail-
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fedipine or placebo, heart rate and blood pressure were
unchanged. A worsening of previously present angina
at rest occurred in five patients who had continued to
experience rest angina before drug withdrawal, four of
whom were withdrawn from nifedipine. No patient with
class I to III angina experienced new onset of rest angina
during drug withdrawal. No patient experienced myo-
cardial infarction. There was no significant difference
between patients withdrawn from nifedipine or placebo
in the duration or frequency of ischemic ST changes on
continuous electrocardiographic monitoring, or in du-
ration or positive resultsofserialexercise treadmill testing.
Thus, no early adverse effects of acute nifedipine
withdrawal were found in patients with prior rest angina
at the time of bypass surgery or in stable patients re-
ceiving long-term medical therapy . Patients with con-
tinued symptoms of rest angina, however, may experi-
enceadverse ischemicevents with nifedipinewithdrawal.
ure, and there have been reports that clonidine withdrawal
causes a profound rebound hypertensive state (5,6).
A similar phenomenon has been reported after acute with-
drawal of calcium antagoni st therapy in patients who have
coronary spasm with persistent rest angina and in patients
undergoing coronary artery bypass surgery (7-13) . In clin-
ical practice, questions regarding the safety of calcium an-
tagonist drug withdrawal usually occur in two settings. The
first is in patients who are no longer experiencing symptoms
of rest angina after an extended period of medical therapy .
Prior prospecti ve studies (14,15) of unstable angina have
demonstrated that most unfavorable outcomes occur within
8 to 12 weeks after the onset of rest angina . The necessity
for extended , long-term medical therapy in patients who
have passed the high risk period and who are no longer
experiencing symptoms of rest angina is uncertain. In ad-
dition, the expense, inconvenience and side effects of a
complex anti-ischemic regimen often prompt the patient
whose condition is stable and the physician to ask if life-
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long therapy is necessary. Also, the value of continued
calcium antagonist therapy is an important question in pa-
tients with persistent symptoms. If patients are continuing
to experience rest angina, the concern may be that the drug
was or has become ineffective and the question of the benefit
and need for continuing therapy arises.
Finally, it is expected that patients undergoing coronary
artery bypass surgery will not require further calcium an-
tagonist therapy and continued treatment is not usually rec-
ommended. However, reports (8,16) of severe coronary
vasospasm and sudden cardiovascular collapse during the
perioperative period have prompted concern about the po-
tential risk of withdrawing calcium antagonist drugs in the
setting of coronary artery bypass surgery. In addition, there
have been reports (17) of an antiplatelet effect of these drugs
which may potentiate postoperative bleeding.
There have been no controlled studies describing the
effect of acute nifedipine withdrawal in these groups of
patients The short-term results of a randomized trial of
nifedipine in patients with unstable angina have previously
been reported (14). The termination of that study in a group
of patients after 2 years of medical treatment and in another
group of patients at the time of coronary artery bypass sur-
gery afforded us a unique opportunity to compare the effects
of withdrawal of nifedipine and placebo in a large group of
patients with prior unstable angina. Our study examines the
question of the existence of an acute nifedipine rebound
withdrawal phenomenon in these patient groups.
Methods
Study patients. Our study group consists of 81 patients
who had been enrolled in a double-blind, randomized,
placebo-controlled trial of nifedipine in addition to conven-
tional medical therapy, including propranolol and long-act-
ing nitrate preparations in those with unstable rest angina
(14). One group of 39 patients taking the blinded study drug
(nifedipine, 80 mg daily, or placebo) underwent coronary
artery bypass surgery for control of persistent angina or left
main coronary disease. Eight additional patients underwent
surgery at other institutions and were unavailable for study.
The study drug was discontinued 1 to 14 hours (mean 5.4)
before surgery and the patients were followed up during the
postoperative period for evidence of the following: coronary
artery spasm, myocardial infarction defined by the appear-
ance of new pathologic Q waves greater than 0.04 second
in duration and serum creatine kinase increase to greater
than twice normal with at least 10% MB fraction, hypoten-
sion requiring intraaortic balloon counterpulsation, post-
operative hypertension defined by systolic pressure greater
than 170 mm Hg, bleeding requiring reoperation or trans-
fusion. vasodilator and vasopressor medication require-
ments, and significant arrhythmias consisting of paroxysmal
atrial tachycardia, atrial fibrillation or flutter and ventricular
tachycardia defined by three or more consecutive ventricular
beats at a rate greater than 100 beats/min. Data are presented
as mean ± standard error.
Thirty-six additional patients successfully completed 2
years of therapy on the randomized double-blind protocol
consisting of nifedipine or placebo in addition to long-acting
nitrates and beta-adrenergic blocking agents. Thirty-two pa-
tients were in stable condition and experiencing no rest
angina, with occasional pain only at more than usual activ-
ity. Four patients were continuing to have rest angina but
were not surgical candidates. In addition, six patients who
had been enrolled in the trial and who were taking open
label nifedipine (one patient after bypass surgery and five
patients who were not operative candidates) also agreed to
be hospitalized for the withdrawal protocol. Four of these
six patients were continuing to experience occasional epi-
sodes of rest angina while taking nifedipine. At 2 years of
therapy, these patients agreed to be admitted to the Clinical
Research Center of the Johns Hopkins Hospital and were
monitored during withdrawal of the study drug. The with-
drawal protocol was approved by the Joint Committee on
Clinical Investigation.
Study protocol. Patients were admitted to the Clinical
Research Center after giving informed written consent and
with the permission of each patient's physician. Initial stud-
ies included history and physical examination, 12 lead elec-
trocardiogram at rest, chest X-ray examination and a graded
symptom-limited exercise treadmill test using a modified
Bruce protocol. Continuous two channel electrocardio-
graphic recording for number and total duration of ischemic
episodes defined by ST segment depression or elevation of
1 mm or greater was performed throughout the hospital stay
(18). After completion of the initial studies, the study drug
was reduced from 20 to 10 mg for one dose and subsequently
discontinued. The patients were monitored for a mean (±
SD) of 66 ± 15 hours after the withdrawal of the study
drug. Twelve lead electrocardiograms were obtained in all
patients who experienced chest discomfort. If there was
electrocardiographic evidence of ischemia, patients were
treated with sublingual nitrates and then started on open
label nifedipine. Those patients who completed the with-
drawal period without recurrent angina underwent repeat
exercise treadmill testing.
Data analysis. The treadmill results and long-term
electrocardiographic data were randomized and reviewed by
two independent observers. The incidence, number and du-
ration of overt and clinically silent ischemic episodes as
detected by continuous electrocardiographic monitoring and
serial exercise treadmill positivity and duration were com-
pared in those patients who were withdrawn from nifedipine
and placebo therapy. Data are presented as mean ± standard
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Table 2. Clinical Outcome of Patients Withdrawn from
Nifedipine and Placebo at Coronary Bypass Surgery*
*There is no statistically significant difference between the groups for
any characteristic listed. Afib '" Atrial fibrillation; CK '" creatine kinase;
PAT", paroxysmal atrial tachycardia; VT '" ventricular tachycardia.
0.3 placebo-treated patients) were also not significantly dif-
ferent between the two groups. The incidence of supraven-
tricular (four nifedipine- and three placebo-treated patients)
and ventricular (four nifedipine- and three placebo-treated
patients) arrhythmias was also the same.
Medical Group
Clinical profiles of the 42 patients who were withdrawn
from nifedipine and placebo after 2 years of therapy are
presented in Table 3. Twenty-five patients were withdrawn
from nifedipine and 17 were withdrawn from placebo. The
groups were similar with respect to age, sex, history of
myocardial infarction and extent of coronary artery disease
error. Noncontinuous data were examined by contingency
table analysis using chi-square tests of significance. Con-
tinuous function variables were analyzed using paired and
nonpaired t tests of significance where appropriate.
Results
Surgical Group
Thirty-nine patients taking the study drug underwent
coronary artery bypass surgery at the Johns Hopkins Hos-
pital for persistent ischemia (31 patients) or for left main
coronary stenosis (8 patients). At the time of surgery, 17
patients were withdrawn from nifedipine and 22 were with-
drawn from placebo (Table 1). There was no significant
difference between the groups with respect to age, sex, left
ventricular ejection fraction, incidence of significant left
main coronary disease, other anti-ischemic medications, the
number of bypass grafts placed or time on cardiopulmonary
bypass. The mean time between the last dose of study drug
and initiation of anesthesia was 5.4 ± 1.8 hours.
Effect of study drug withdrawal (Table 2). The in-
traaortic balloon pump was required for hypotension in one
patient who was withdrawn from nifedipine and three who
were withdrawn from placebo. One nifedipine- and two
placebo-treated patients sustained a perioperative myo-
cardial infarction, and two in each group had perioperative
hypertension. There was no significant difference between
the groups with respect to the number of patients who re-
ceived vasopressors (9 nifedipine- and 9 placebo-treated
patients), vasodilators (15 nifedipine- and 20 placebo-treated
patients) or the maximal dose or duration of either therapy.
No patient had postoperative bleeding that required reoper-
ation. The mean number of red cell units transfused post-
operatively (3.0 ± 0.6 for nifedipine- and 3.4 ± 0.4 pla-
cebo-treated patients) and the mean number of days of
intensive care unit stay (2.8 ± 0.4 nifedipine- and 3.1 ±
Hypotension requiring
intraaortic balloon
Perioperative hypertension
(systolic> 170 mm Hg)
Perioperative myocardial infarction
(new Q waves, CK-MB increase)
Vasopressor therapy
Duration (hr)
Vasodilator therapy
Duration (hr)
Maximal dose (/Lg/kg per min)
Red cell transfusions (units)
Intensive care unit stay (days)
Arrhythmias
PAT, Afib or flutter
VT (three or more beats)
Nifedipine
(n '" 17)
2
9
23.3 ± 7.3
15
23.5 ± 4.1
11.7 ± 3.3
3.0 ± 0.6
2.8 ± 0.4
4
4
Placebo
(n '" 22)
3
2
2
9
34.4 ± 10.3
20
27.6 ± 3.6
13.9 ± 2.5
3.4 ± 0.4
3.1 ± 0.3
3
3
Table 1. Clinical Characteristics of Patients Withdrawn From
Nifedipine and Placebo at Coronary Bypass Surgery*
Nifedipine
(n '" 17)
Placebo
(n '" 22)
Table 3. Clinical Characteristics of Patients Withdrawn From
Nifedipine and Placebo at 2 Years
Age (yr)
Sex (M/F)
Ejection fraction (%)
Left main coronary artery stenosis > 50%
(no. of patients)
Medications
Propranolol (rng/day)
Nitrates, topical (inches/day)
Number of grafts
Cardiopulmonary bypass time (min)
58 ± 3
12/5
61 ± 3
4
277 ± 43
14 ± 2
2.9 ± 0.2
117 ± 13
57 ± 2
18/4
63 ± 4
4
278 ± 45
15.7 ± 2
3.0 ± 0.2
103 ± 8
Age (yr)
Sex (M/F)
Prior myocardial infarction
Coronary lesion > 70%
(no. of patients)
Medications
Propranolol (mg/day)*
Nitrates (rng/day)
Nifedipine
(n = 25)
63 ± 2
17/8
16
16/18
177 ± 13
109 ± II
Placebo
(n > 17)
65 ± 2
10/7
II
8110
282 ± 41
92 ± 17
*There is no statistically significant difference between the groups for
any characteristic listed. F '" female; M '" male.
*p = 0.053. There is no statistically significant difference between
the groups for any other characteristic listed. F '" female; M = male.
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Figure l. The number of patients who did
and did not experience rest angina during
the period of withdrawal of nifedipine and
placebo . Note the absence ofrecurrent rest
angina in the 34 patient s in stable condition
with class I to III angina before withdrawal.
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as determined by angiography . Although nitrate doses were
similar. the mean dose of propranolol was lower in the group
that was withdrawn from nifedipine.
Angina during the withdrawal period. During the ob-
servation period after the withdrawal of nifedipine or pla-
cebo , five of eight patient s in the group with persistent rest
angina before drug withdrawal had a significant worsening
of their angina as evidenced by severe rest angina associated
with ischemic electrocardiographic change s. Of these five
patients. four were withdrawn from nifedipine (two blinded
and two open label) and one was withdrawn from placebo .
Howev er , none of the 34 patients who were no longer ex-
periencing rest angina before drug withdrawal had a wors-
ening of their anginal pattern or the new development of
rest angina (Fig. 1). Nifedipine therapy was initiated in the
five patient s who subsequently had no recurrent episodes of
rest angina. No patient experienced myocardial infarction
after drug withdrawal.
Exercise performance (Fig. 2, Table 4). There was no
evidence in either group of a significant change in heart rate
at rest or blood pressure during the withdrawal period. There
was no significant difference between the groups in the
number of patients with a positive test , total exercise du-
ration, work load expre ssed as heart rate-systolic pressure
15 mON STUDY DRUG
o OFF STUDY DRUG
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Figure 2. The total durat ion of treadmill
exercise before and after withdrawal of
nifedipine and placebo . There is no sig-
nificant difference between the two groups.
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Table 4. Results of Exercise Treadmill Testing During and 48
Hours After Withdrawal of Nifedipine or Placebo Therapy*
*There is no statistically significant difference between the two groups
for any variable listed. tTreadmill testing performed in 22 nifedipine- and
16 placebo-treated patients. BP = blood pressure; HR = heart rate.
product, or time to the onset of ST shift in those patients
with a positive test.
Long-term electrocardiographic monitoring. The re-
sults of continuous electrocardiographic monitoring for a
mean of 66 hours during the study drug withdrawal period
are shown in Figure 3. There was no significant difference
between the groups with regard to the total number of ep-
isodes of ischemicST segmentshift per 24 hours (nifedipine
0.78 ± 0.07 and placebo 0.73 ± 0.11) or total duration
of ST segment shift per 24 hours (nifedipine 24.5 ± 3.3
minutes and placebo 22.6 ± 5.0 minutes) during the with-
drawal period. The data were also examined separately for
each 12 hour period for evidence of any time-dependent
increase in silent ischemia, but none was found in either
treatment group.
Total duration (min)
During therapy
After withdrawalt
Positivity (ST shift> I mm)
During therapy
After withdrawal
Time of onset of ST shift (min)
During therapy
After withdrawal
HR x BP (beats/min x mm Hg)
During therapy
After withdrawal
Nifedipine
(n = 25)
8.2 ± 0.8
9.5 ± 0.9
II
9
6.2 ± 0.6
6.1 ± 0.7
18,048 ± 1,136
17,672 ± 1,132
Placebo
(n = 17)
6.4 ± 0.9
7.4 ± 0.8
8
10
5.3 ± 0.6
6.6 ± 0.7
16,673 ± 1,475
14,741 ± 1,409
Discussion
Reports of uncontrolled studies have suggested an acute
ischemic rebound phenomenon after nifedipine withdrawal
in some patients. In one study (7), five of seven patients in
a nonrandomized trial of nifedipine for unstable angina had
recurrent rest angina and one had a fatal infarction within
48 hours of withdrawal or tapering of nifedipine. Another
report (8) suggested that severe postoperative coronary spasm
in one patient may have been due to nifedipine withdrawal
at the time of bypass surgery. A recent controlled study (9)
of the effect of nifedipine withdrawal in patients with con-
tinuing rest angina demonstrated a worsening of anginal
symptoms in 7 of 19 patients in whom nifedipine was with-
drawn as comparedwith only 1 of 19 who continued to take
nifedipine. Two of the patients who demonstrated a signif-
icant increase in anginal symptoms had been concomitantly
withdrawn from both nitrates and beta-adrenergic blocking
agents. These prior reports refer to patients studied soon
after starting nifedipine or in whom significant rest symp-
toms persisted despite calcium antagonist therapy.
Our report describes a controlled trial of nifedipine with-
drawal in patients who had extensive coronary disease at
the time of coronary artery bypass surgery or after 2 years
of medical therapy. Other medications were continued so
that our observations can be attributed exclusively to with-
drawal of nifedipine or placebo.
Nifedipine withdrawal at bypass surgery. In patients
.undergoing coronary artery bypass surgery, it is expected
that further anti-ischemic drug treatment is not required and
it is not routinely recommended. However, the recognition
of the syndrome of severe coronary spasm in the periop-
erative period has focused attention on the potential hazard
of abrupt withdrawal of calcium channel blocker therapy.
For some of these drugs (nifedipine, for example) acute
withdrawal is routine since light inactivation may occur
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despite parenteral administration (19), and hemodynamic
instability in the perioperative period may preclude the use
of potent vasodilators. Although perioperative coronary ar-
tery spasm has been well documented (16), we found no
evidence to suggest that this phenomenon is either induced
or exacerbated by perioperative nifedipine withdrawal. Fur-
thermore, there was no evidence of an association between
perioperative hemodynamic instability, bleeding or signif-
icant arrhythmias and nifedipine withdrawal in these patients.
Nifedipine withdrawal after long-term therapy.
Consequences of drug withdrawal are also of concern in
patients whose anginal pattern has stabilized for an extended
period of time on medical therapy. The long-term expense,
inconvenience and potential side effects of these medica-
tions are appreciable. If the drug was initially utilized for
a vasospastic state such as unstable angina, remission may
occur making long-term therapy unnecessary. In our patients
with prior rest angina whose condition had stabilized on a
medical regimen consisting of nitrates, beta-adrenergic
blocking agents and either nifedipine or placebo and who
were no longer experiencing rest angina, there was no evi-
dence of clinically significant acute ischemic events after
nifedipine withdrawal. Therefore, the early risk of nifedi-
pine withdrawal in these patients appears to be minimal. In
contrast, of the eight patients who continued to experience
occasional episodes of rest angina, five had an acute wors-
ening \) f their anginal pattern after withdrawal of the study
medication (four nifedipine and one placebo-treated pa-
tient). Thus, our findings support previous studies (7,9)
suggesting that nifedipine withdrawal in patients with per-
sistent rest angina may be associated with a significant risk
of adverse ischemic events.
Limitations of study. First, these results apply only to
patiems in whom nifedipine has been withdrawn and who
have been maintained on propranolol and long-acting nitrate
therapy. It is not known whether these results apply if pa-
tients are receiving nifedipine as their only antianginal agent.
Second, the length of in-hospital observation, a mean period
of 66 hours after drug withdrawal, was relatively short and
allowed for observation of only acute effects. Although this
withdrawal period was longer than that in prior reports de-
scribing significant rebound effects, we do not know if fur-
ther adverse effects would have occurred over an extended
withdrawal period. In addition, the patients available for
study at 2 years were those who had responded to medical
therapy and not those who had bypass surgery and, thus,
were not representative of the total group. Because nife-
dipine was effective in decreasing the need for surgery (14),
those patients receiving placebo may have had less severe
disease, thus creating a potential bias in favor of the placebo
group. However, no significant adverse effects were noted
in either patient group at the time of bypass surgery or at
2 years in the patients whose condition had stabilized on
medical therapy.
Implications. Those patients with rest angina who undergo
coronary artery bypass surgery or whose condition has sta-
bilized on medical therapy demonstrated no acute adverse
effects from nifedipine withdrawal. This suggests that life-
time therapy with calcium channel blocker medications may
not be necessary after the high risk period has passed. Prior
studies (14,15,20,21) suggest that the period of highest risk
after the development of angina is variable and may last for
only 8 to 12 weeks. Acute endothelial injury and subsequent
healing is a recognized sequence of events accompanying
the development of atherosclerosis (22), and it is possible
that endothelial injury may be both caused by spasm and
result in an increased susceptibility for further coronary
spasm until healing occurs. Alternatively, the high incidence
of early adverse events may be related to a hypercoagulable
state after plaque disruption. The uneventful acute with-
drawal from effective calcium antagonist therapy in these
patients with prior rest angina whose condition has stabilized
on treatment supports the concept that the development of
unstable angina with its attendant short-term risk of death,
myocardial infarction and continued angina requiring sur-
gery may represent only a transient period of instability.
In contrast, there may be some risk associated with ni-
fedipine withdrawal in patients who continue to experience
symptoms of rest angina, suggesting a continued benefit of
therapy in those patients with a continuing predisposition
to vasospasm. Thus, these patients would appear to benefit
from long-term calcium antagonist therapy.
We thank Mrs. Spring Metcalf for her secretarial assistance in the prep-
aration of this manuscript.
References
I. Barsotti OM. Attacchi stenocardici nei lavoratori addetti alia produ-
zione delle dinamiti con nitrogliocole. Med Lav 1954;45:544-8.
2. Carmichael P, Lieben J. Sudden death in explosives workers. Arch
Environ Health 1963;7:424-39.
3. Morikawa Y, Muraki K, Ikowa Y, Honda T. Takamatsu H. Organic
nitrate poisoning at an explosives factory. Arch Environ Health
1967;14:614-21.
4. Lange RL. Reid MS, Tresch DO. et al. Nonatheromatous ischemic
heart disease following withdrawal from chronic industrial nitrogly-
cerine exposure. Circulation 1972;46:666-78.
5. Packer M, Meller J, Medina N. Godin R. Herman MY. Rebound
hemodynamic events after the abrupt withdrawal of nitroprusside in
patients with severe chronic heart failure. N. Engl J Med 1979;
301:1193-7.
6. Whitsett TL. Chrysant SG. Dillard BL. et al. Abrupt cessation of
clonidine administration: a prospective study. Am J Cardiol
1978;41:1285-90.
7. Moses JW. Wertheimer JH. Bodenheimer MM. et al. Efficacy of
nifedipine in rest angina refractory to propranolol and nitrates in pa-
tients with obstructive coronary artery disease. Ann Intern Med
1981;94:425~9.
8. Kay R, Blake J, Rubin D. Possible coronary spasm rebound to abrupt
nifedipine withdrawal (letter). Am Heart J 1982;103:308.
388 GOTTLIEB ET AL.
ACUTE NIFEDIPINE WITHDRAWAL
lACC Vol. 4, No.2
August 1984:382-8
9. Schick EC, Liang C, Heupler FA, et al. Randomized withdrawal from
nifedipine: placebo-controlled study in patients with coronary artery
spasm. Am Heart 1 1982;104:690-6.
10. Freedman SB, Richmond DR, Kelly DT. Long-term follow-up of
verapamil and nitrate treatment for coronary artery spasm. Am 1 Car-
diol 1982;50:711-5.
II. Scheidt S, Frishman WH, Packer M, et al. Long-term effectiveness
of verapamil in stable and unstable angina pectoris. Am 1 Cardiol
1982;50:1185-90.
12. Frishman WH, Klein N, Strom 1, et al. Comparative effects of abrupt
withdrawal of propranolol and verapamil in angina pectoris. Am 1
Cardiol 1982;50:1191-5.
13. Gerber IG, Nies AS. Abrupt withdrawal of cardiovascular drugs. N
Engl1 Med 1979;301:1234-5.
14. Gerstenblith G, Ouyang P, Achuff SC, et <II. Nifedipine in unstable
angina: a double-blind, randomizedtrial. N Engl1 Med 1982;306:885-9.
15. Russell RO, Moraski RE, Kouchoukos N, et al. Unstable angina
pectoris: National Cooperative Study to compare medical and surgical
therapy. II. In-hospital experience and initial follow-up results in pa-
tients with one, two and three vessel disease. Am 1 Cardiol
1978;42:839-48.
16. Buxton AE, Goldberg S, Harken A, Hirshfeld 1, Kastor lA. Coronary
artery spasm immediately after myocardial revascularization. N Engl
1 Med 1981;304:1249-53.
17. Dale 1, Landmark KH, Myhre E. The effect of nifedipine, a calcium
antagonist, on platelet function. Am Heart 11983;105:103-5.
18. Armstrong WF, Morris SN. The ST segment during ambulatory
electrocardiographic monitoring. Ann Intern Med 1983;98:249-51.'
19. Morad M, Goldman YE, Trentham DR. Rapid photochemical inac-
tivation of Cal + antagonists shows that Ca2 + entry directly activates
contraction in frog heart. Nature 1983;304:635-8.
20. Gazes PC, Mobley EM Jr, Faris HM Jr, Duncan RC, Humphries GB.
Preinfarctional (unstable) angina-a prospective study-ten year fol-
low-up. Circulation 1973;48:331-7.
21. Kannel WB, Sorlie PD. Remission of clinical angina pectoris: the
Framingham study. Am 1 Cardiol 1978;42:119-23.
22. Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl 1
Med 1976;295:369-77,420-5.
